Romosozumab

Editorial from The New England Journal of Medicine — Building Better Bones with Biologics — A New…
nejm.org

With Denosumab and Romosozumab in its stable, this is Amgen's Osteoporosis Decade.
They are easily the best in their own class (anti-resoptive, bone former). Whether you combine them or cycle them, their net effect is likely to be synergistic rather than merely additive.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Original Article from The New England Journal of Medicine — Romosozumab Treatment in Postmenopausal Women with Osteoporosis
nejm.org

FRAME: Romosozumab Rapidly Reduces Fracture Risk in Osteoporosis

Romosozumab rapidly and dramatically reduces vertebral fractures compared with placebo in FRAME, and bone-enhancing effects continue after patients are…
medscape.com

Sclerostin Inhibitor Cuts Fractures in Women

Relative risk reduction of 73% for vertebral fractures in year 1 with romosozumab
medpagetoday.com

Anti-Sclerostin Drug Prevents Vertebral Fractures in Post-Menopausal Osteoporosis

Romosozumab is being developed as a novel therapy for osteoporosis. It is a monoclonal antibody that binds sclerostin, and has been shown to increase bone formation while decreasing bone resorption.
rheumnow.com

Comments are closed.